360 related articles for article (PubMed ID: 10320528)
21. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D; Berruti A; Tampellini M; Dovio A; Tedoldi S; Bonardi S; Tucci M; Allevi G; Aguggini S; Milani M; Bottini A; Dogliotti L; Angeli A
Bone; 2007 Jan; 40(1):182-8. PubMed ID: 16935041
[TBL] [Abstract][Full Text] [Related]
22. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
[TBL] [Abstract][Full Text] [Related]
23. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
[TBL] [Abstract][Full Text] [Related]
24. [Bone resorption markers].
Takahashi M; Inoue T
Rinsho Byori; 1996 May; 44(5):415-22. PubMed ID: 8676559
[TBL] [Abstract][Full Text] [Related]
25. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
26. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
[TBL] [Abstract][Full Text] [Related]
27. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
28. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
29. Comparison of serum and urinary C-terminal telopeptide of type I collagen in aging, menopause and osteoporosis.
Kawana K; Takahashi M; Hoshino H; Kushida K
Clin Chim Acta; 2002 Feb; 316(1-2):109-15. PubMed ID: 11750280
[TBL] [Abstract][Full Text] [Related]
30. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen.
Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C
J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001
[TBL] [Abstract][Full Text] [Related]
31. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
[TBL] [Abstract][Full Text] [Related]
32. [Relationship of osteolytic biochemical indicators of bone metabolism with the therapeutic effect in breast cancer patients with bone metastases].
Li SF; Wang XR; Wang C; Chen Y; Ren L; Cui L; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):911-5. PubMed ID: 20193330
[TBL] [Abstract][Full Text] [Related]
33. Comparison of bone resorption markers during hypocalcemia in dairy cows.
Liesegang A; Sassi ML; Risteli J; Eicher R; Wanner M; Riond JL
J Dairy Sci; 1998 Oct; 81(10):2614-22. PubMed ID: 9812267
[TBL] [Abstract][Full Text] [Related]
34. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women.
Ivaska KK; Gerdhem P; Akesson K; Garnero P; Obrant KJ
J Bone Miner Res; 2007 Aug; 22(8):1155-64. PubMed ID: 17488197
[TBL] [Abstract][Full Text] [Related]
35. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
36. Effects of age, menopause and osteoporosis on free, peptide-bound and total pyridinium crosslink excretion.
Del Campo MT; González-Casaus ML; Aguado P; Bernad M; Carrera F; Martínez ME
Osteoporos Int; 1999; 9(5):449-54. PubMed ID: 10550465
[TBL] [Abstract][Full Text] [Related]
37. Biochemical assessment of Paget's disease of bone.
Shankar S; Hosking DJ
J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
[TBL] [Abstract][Full Text] [Related]
38. Automated and manual assays for urinary crosslinks of collagen: which assay to use?
Seibel MJ; Woitge HW; Farahmand I; Oberwittler H; Ziegler R
Exp Clin Endocrinol Diabetes; 1998; 106(2):143-8. PubMed ID: 9628247
[TBL] [Abstract][Full Text] [Related]
39. Immobilization-dependent bone collagen breakdown appears to increase with time: evidence for a lack of new bone equilibrium in response to reduced load during prolonged bed rest.
Fiore CE; Pennisi P; Ciffo F; Scebba C; Amico A; Di Fazzio S
Horm Metab Res; 1999 Jan; 31(1):31-6. PubMed ID: 10077347
[TBL] [Abstract][Full Text] [Related]
40. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
